Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report)’s share price traded up 0.6% during mid-day trading on Tuesday . The company traded as high as $13.1850 and last traded at $13.1850. Approximately 6,192 shares traded hands during mid-day trading, an increase of 53% from the average daily volume of 4,043 shares. The stock had previously closed at $13.11.
Innovent Biologics Stock Performance
The firm’s 50 day moving average is $12.20 and its 200 day moving average is $11.11.
Innovent Biologics Company Profile
Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.
The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).
Further Reading
- Five stocks we like better than Innovent Biologics
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
